| |
| |
|
| Insider
Information: |
Vessey Rupert |
| Relationship: |
EVP & President, Resea... |
| City: |
Summit |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
55,636 |
|
|
Indirect Shares
|
656 |
|
|
| Direct
Value |
$2,531,094 |
|
|
|
Indirect Value
|
$26,404 |
|
|
| Total
Shares |
56,292 |
|
|
| Total
Value |
$2,557,498 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
6
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 9.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2023-10-26 |
7,885 |
2019-07-01 |
0 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
EVP & President, Resea... |
2023-05-03 |
47,751 |
2023-05-03 |
656 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
79 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-12-31 |
4 |
D |
$62.03 |
$822,332 |
D/D |
(13,257) |
54,817 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-11-23 |
4 |
S |
$61.34 |
$823,244 |
D/D |
(13,421) |
37,922 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
14,178 |
14,178 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,247 |
81,213 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,060 |
30,778 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,245 |
62,384 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-16 |
4 |
S |
$61.99 |
$1,196,252 |
D/D |
(19,298) |
31,960 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-31 |
4 |
D |
$62.35 |
$1,436,108 |
D/D |
(23,033) |
53,956 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,349 |
48,106 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,349 |
80,572 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,350 |
79,587 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,866 |
68,074 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-05-05 |
4 |
S |
$64.29 |
$1,963,802 |
D/D |
(30,546) |
45,139 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
D |
$65.71 |
$2,529,704 |
D/D |
(38,498) |
98,136 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,029 |
76,989 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-11-07 |
4 |
S |
$78.88 |
$3,621,381 |
D/D |
(45,910) |
57,079 |
0 |
% |
|
| CELG |
Celgene Corp |
PRES., RESEARCH AND EARLY DEV. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
46,749 |
60,927 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-16 |
4 |
OE |
$38.41 |
$2,696,612 |
D/D |
47,305 |
93,613 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-05-03 |
4 |
S |
$67.06 |
$3,378,818 |
D/D |
(50,385) |
47,751 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-11-19 |
4 |
OE |
$38.41 |
$2,572,887 |
D/D |
52,213 |
98,355 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-11-07 |
4 |
OE |
$38.41 |
$3,067,529 |
D/D |
52,604 |
102,989 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-11-19 |
4 |
S |
$61.25 |
$3,530,269 |
D/D |
(57,591) |
51,343 |
0 |
% |
|
| CELG |
Celgene Corp |
PRES., RESEARCH AND EARLY DEV. |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,927) |
0 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,935 |
118,263 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-16 |
4 |
S |
$69.23 |
$5,162,973 |
D/D |
(74,559) |
50,385 |
0 |
% |
|
79 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
